Travere Therapeutics Inc.

18 hours ago · businesswire.com

SAN DIEGO--(BUSINESS WIRE)---- $TVTX--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that Eric Dube, Ph.D., has made the difficult and personal decision to step down as president and chief executive officer to focus on his health and family. The Company's Board of Directors has unanimously appointed Bradley L. Campbell, former president and CEO of Amicus Therapeutics, now a wholly owned subsidiary of BioMarin Pharmaceutical Inc., to succeed Dr. Dube as president and chief executive officer and.

2 days ago · defenseworld.net

Travere Therapeutics, Inc. (NASDAQ: TVTX - Get Free Report) EVP Peter Heerma sold 8,282 shares of the company's stock in a transaction on Thursday, September 17th. The stock was sold at an average price of $65.07, for a total value of $538,909.74. Following the sale, the executive vice president owned 117,066 shares of the company's stock,

2 days ago · defenseworld.net

Travere Therapeutics, Inc. (NASDAQ: TVTX - Get Free Report) insider Elizabeth Reed sold 37,500 shares of the firm's stock in a transaction that occurred on Tuesday, September 15th. The stock was sold at an average price of $62.34, for a total transaction of $2,337,750.00. Following the sale, the insider owned 105,389 shares in the company, valued

4 days ago · businesswire.com

SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that company management will present at the Stifel 2026 Virtual Immunology and Inflammation Forum on Thursday, September 24, 2026, at 10:30 a.m. ET.Live webcast of the presentation will be accessible on the Investor page of Travere's website at ir.travere.com/events-and-presentations. Replay will be available for up to 30 days following the event.About Travere TherapeuticsAt Travere Therapeutics, we are in rare.

1 month ago · seekingalpha.com

Travere Therapeutics is rated Buy, with a DCF-based fair value of ~$81 per share, implying 27% upside. FILSPARI's commercial ramp is strong, posting $141.1M in Q2 U.S. sales and targeting a $3B+ peak sales opportunity across IgAN and FSGS. My model assumes modest FILSPARI penetration, conservative pricing, and accounts for royalty burdens, tax credits, and IP risks.

1 month ago · marketbeat.com

Travere Therapeutics NASDAQ: TVTX is pursuing growth through expanded use of FILSPARI in rare kidney diseases while advancing a late-stage treatment candidate for classical homocystinuria and building its renal pipeline through the recently in-licensed BTK inhibitor civorebrutinib, Chief Financial Officer Chris Cline said at a Canaccord Genuity discussion.

2 months ago · seekingalpha.com

Travere Therapeutics is downgraded from Buy to Hold after a >130% rally, reflecting competitive risks and valuation concerns. Filspari's Q2 net sales surged 96% YoY to $141M, but $3B+ peak sales guidance faces new competition in IgAN and FSGS markets. TVTX's pipeline expansion with civorebrutinib and pegtibatinase targets rare kidney and metabolic diseases, but both remain early-stage with uncertain timelines.

2 months ago · businesswire.com

SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that company management will participate in the following upcoming investor conferences: Canaccord Genuity's 46th Annual Growth Conference Presenting on Tuesday, August 11, 2026, at 3:00 p.m. ET Wells Fargo 21st Annual Healthcare Conference Tuesday, September 8, 2026 Citi 2026 Biopharma Back to School Conference Wednesday, September 9, 2026 2026 Cantor Global Healthcare Conference Presenting on Thursday, Septe.

2 months ago · marketbeat.com

Travere Therapeutics NASDAQ: TVTX reported second-quarter results marked by record FILSPARI demand and revenue, driven by continued growth in IgA nephropathy and an early launch in focal segmental glomerulosclerosis, or FSGS.

2 months ago · seekingalpha.com

Travere Therapeutics, Inc. (TVTX) Q2 2026 Earnings Call Transcript